Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T18:20:57.840Z.
Calculation as of: 2026-10-06T18:20:57.840Z.
Quote observation: 2026-10-06T18:19:38.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1c5d1a4dd2ed90e95308857a7b7df8ea0860f9bef9a655807fa9e02aea5f37e0
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Cellectar Biosciences, Inc.
Market Cap
$12.54M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.51M
Operating Cash Flow Yield
N/A
TTM Avg
26.92%
3Y Avg
26.92%
5Y Avg
26.92%
Market Cap
$12.44M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.43M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.66M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.73M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.19M
Operating Cash Flow Yield
N/A
TTM Avg
10.50%
3Y Avg
10.50%
5Y Avg
10.50%
Market Cap
$13.33M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cellectar Biosciences, Inc. (CLRB) | $12.54M | N/A | N/A | N/A | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.51M | N/A | 26.92% | 26.92% | 26.92% |
| Lantern Pharma Inc. (LTRN)vs › | $12.44M | N/A | N/A | N/A | N/A |
| Tempest Therapeutics, Inc. (TPST)vs › | $12.43M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.66M | N/A | N/A | N/A | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.73M | N/A | N/A | N/A | N/A |
| IRIDEX Corporation (IRIX)vs › | $12.19M | N/A | 10.50% | 10.50% | 10.50% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.33M | N/A | N/A | N/A | N/A |
| IN8bio, Inc. (INAB)vs › | $13.33M | N/A | N/A | N/A | N/A |
| Passage Bio, Inc. (PASG)vs › | $13.40M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
